[1] Queiroz-Telles F, de Hoog S, Santos DW, et al. Chromoblastomycosis[J]. Clin Microbiol Rev,2017, 30(1):233-276.
[2] Lu S, Lu C, Zhang J, et al. Chromoblastomycosis in Mainland China:a systematic review on clinical characteristics[J]. Mycopathologia,2013, 175(5-6):489-495.
[3] Li Y, Xiao J, de Hoog GS, et al. Biodiversity and human-pathogenicity of Phialophora verrucosa and relatives in Chaetothyriales[J]. Persoonia,2017, 38(1):1-19.
[4] Wang X, Zhang R, Wu W, et al. Impaired specific antifungal immunity in CARD9-deficient patients with phaeohyphomycosis[J]. J Invest Dermatol,2018, 138(3):607-617.
[5] Wang X, Wang W, Lin Z, et al. CARD9 mutations linked to subcutaneous phaeohyphomycosis and TH17 cell deficiencies[J]. J Allergy Clin Immunol,2014, 133(3):905-908.e3.
[6] Agarwal R, Singh G, Ghosh A, et al. Chromoblastomycosis in India:Review of 169 cases[J]. PLoS Negl Trop Dis,2017, 11(8):e0005534.
[7] 张逸,王晓雯,李若瑜. CARD9突变在真菌感染性疾病中的研究进展[J]. 微生物与感染,2018, 13(4):233-244.
[8] Huang C, Zhang Y, Song Y, et al. Phaeohyphomycosis caused by Phialophora americana with CARD9mutation and 20-year literature review in China[J]. Mycoses,2019, 62(10):908-919.
[9] Lyon JP, Pedroso e Silva Azevedo Cde M, Moreira LM, et al. Photodynamic antifungal therapy against chromoblastomycosis[J]. Mycopathologia,2011, 172(4):293-297.
[10] Queiroz-Telles F, Santos DW. Challenges in the therapy of chromoblastomycosis[J]. Mycopathologia,2013, 175(5-6):477-488.